- Home
- KOD vs MOLN Comparison
KOD vs MOLN Comparison
Compare KOD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- MOLN
- Stock Information
- Founded
- KOD 2009
- MOLN 2004
- Country
- KOD United States
- MOLN Switzerland
- Employees
- KOD N/A
- MOLN N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- MOLN
- Sector
- KOD Health Care
- MOLN
- Exchange
- KOD Nasdaq
- MOLN Nasdaq
- Market Cap
- KOD 186.3M
- MOLN 218.1M
- IPO Year
- KOD 2018
- MOLN 2021
- Fundamental
- Price
- KOD $5.90
- MOLN $5.42
- Analyst Decision
- KOD Hold
- MOLN Hold
- Analyst Count
- KOD 5
- MOLN 1
- Target Price
- KOD $3.50
- MOLN $4.50
- AVG Volume (30 Days)
- KOD 418.9K
- MOLN 17.4K
- Earning Date
- KOD 11-26-2024
- MOLN 08-26-2024
- Dividend Yield
- KOD N/A
- MOLN N/A
- EPS Growth
- KOD N/A
- MOLN N/A
- EPS
- KOD N/A
- MOLN N/A
- Revenue
- KOD N/A
- MOLN $7,105,397.00
- Revenue This Year
- KOD N/A
- MOLN N/A
- Revenue Next Year
- KOD N/A
- MOLN $29.41
- P/E Ratio
- KOD N/A
- MOLN N/A
- Revenue Growth
- KOD N/A
- MOLN N/A
- 52 Week Low
- KOD $2.19
- MOLN $3.32
- 52 Week High
- KOD $7.77
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- KOD 80.20
- MOLN 47.39
- Support Level
- KOD $5.08
- MOLN $5.11
- Resistance Level
- KOD $6.00
- MOLN $6.15
- Average True Range (ATR)
- KOD 0.38
- MOLN 0.39
- MACD
- KOD 0.06
- MOLN -0.09
- Stochastic Oscillator
- KOD 94.14
- MOLN 27.43
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.